Explore our blogs on various markets

August 2, 2025 | Thousand Oaks, CA — Amgen has officially announced Meritide (formerly MariTide, maridebart cafraglutide), its groundbreaking investigational therapy for obesity, type 2 diabetes, and related cardiometabolic conditions, marking a bold step forward in the global fight against metabolic disease.. A breakthrough in obesity and diabetes management. In results from its Phase 2 clinical trial, Meritide showed strong and steady weight loss in adults living with obesity, both with and without type 2 diabetes...

Eli Lilly has officially acquired Verve Therapeutics, a pioneering biotech company specializing in in vivo gene editing for cardiovascular disease. The deal, announced on July 25, 2025, is valued at up to $1.3 billion. . It includes an upfront cash payment of $10.50 per share and a contingent value right (CVR) that may provide an additional $3.00 per share if Verve’s lead candidate reaches a U.S...

On July 22, 2025, Sanofi announced a definitive agreement to acquire Vicebio, a clinical-stage biotechnology company developing next-generation respiratory vaccines. The deal is valued at $1.6 billion and includes a $1.15 billion upfront payment with up to $450 million in milestone-based payments. The acquisition aims to expand Sanofi’s respiratory vaccine portfolio through access to Vicebio’s proprietary Molecular Clamp technology....

Clinical development is a long and expensive process. It often takes years of planning, testing, and data collection to bring a new medicine to market. Even then, most clinical trials do not succeed...

Clinical trials help test if new medicines are safe and effective. But many trials fail to find enough people or keep them until the end. One reason is that trial designs often do not match what patients need or want....

Generative AI is transforming the way pharmaceutical companies operate. It helps teams discover drugs faster, write documents quicker, and find insights in huge amounts of data. Instead of doing everything manually, experts can now use GenAI to save time and focus on what matters most—patient care and innovation....

Summary:. Roche, one of the world’s biggest drugmakers, is thinking about selling its medicines directly to patients in the United States. The company’s CEO, Thomas Schinecker, said this plan could help reduce the high cost of prescription drugs in the country...

Roivant Sciences is developing brepocitinib, a new oral drug that blocks both TYK2 and JAK1. These proteins play a key role in autoimmune diseases like dermatomyositis and lupus. . Brepocitinib targets several harmful signals in the body, not just one, which may make it more effective than older treatments...

Summary. Roche has officially initiated the global rollout of Lunsumio® (mosunetuzumab) for the treatment of adult patients with third-line and beyond relapsed or refractory follicular lymphoma (FL). The fixed-duration, off-the-shelf, T-cell engaging bispecific antibody has already been commercially used in over 2,400 patients, according to company data, with significant adoption across major oncology markets....

Zomedica Pharmaceuticals has released a new and improved canine cortisol assay for its TRUFORMA point-of-care diagnostic platform. . The assay allows veterinarians to diagnose Cushing’s syndrome and Addison’s disease within minutes, using a simple in-clinic process. . Previously, such diagnoses required shipping blood samples to external labs and waiting one or two days for results...

Discover the top 5 generative AI tools transforming drug discovery with faster molecule design, target prediction, and real-world pharma applications.. Generative AI has almost transformed how drug discovery works today. In the last five years, it has gone from being a research experiment to a practical tool used by biotech firms and pharmaceutical companies around the world. ...

The market for generic immunology drugs in the Asia-Pacific (APAC) region is witnessing rapid expansion, driven by increasing healthcare access, rising chronic disease prevalence, and cost-containment measures by governments. . As more biologics go off-patent, pharma companies are moving quickly to introduce affordable generic and biosimilar alternatives across key APAC markets.. If you are planning to enter or expand in this space, pricing is one of the most critical levers for success...

In 2025, the pharmaceutical industry is seeing major changes in drug development, pricing, and delivery. AI is speeding up R&D, GLP-1 drugs are redefining obesity treatment, and precision medicine is becoming standard. . This guide breaks down the top trends shaping pharma this year, with real examples and their impact on healthcare and business....

Artificial Intelligence (AI) is changing modern healthcare by helping doctors make faster, smarter decisions. From diagnosing diseases to personalizing treatments and reducing paperwork, AI is making care more accurate and efficient. . With the global AI healthcare market expected to reach nearly $96 billion by 2033, it's clear that AI is no longer just a future trend—it’s a key part of today’s medical systems. ...

AI is changing how we discover new medicines. Instead of testing each idea in a lab, AI studies massive medical data to quickly find the most promising drug candidates. . This speeds up research, lowers costs, and improves success rates...

Several large language models (LLMs) are already being used or evaluated by pharmaceutical companies and health tech teams. From accelerating drug discovery to streamlining regulatory submissions and enhancing patient education, LLMs are redefining how life sciences teams work with data, documents, and decisions.. Unlike traditional AI systems, LLMs can read, understand, and generate natural language at scale, making them ideal for navigating the complexity of biomedical literature, clinical protocols, compliance guidelines, and real-world evidence....

Generative AI is helping doctors and scientists design personalized medicine faster and more accurately. These AI tools use medical, genetic, and clinical data to create treatment plans, drugs, and predictions that match an individual’s unique biology.. Researchers and biotech companies are now using generative AI (GenAI) models to improve patient care...

AI and ML imaging tools are now central to drug discovery. These systems process cell images to detect drug effects, predict safety, and optimize compounds. In this news article, you will find how AI and ML-based imaging are reshaping drug discovery in 2025....

Regulatory impact assessment (RIA) is an essential step for ensuring pharmaceutical product compliance, quality, and safety whenever changes occur in products or their manufacturing processes. However, this process has traditionally been complex and time-consuming, with risks of delaying product availability and increasing regulatory workload.. Today, Generative AI (GenAI) is rapidly changing this landscape, presenting new opportunities for efficiency and accuracy across global pharma operations....

It processes over one thousand interactions per week on cloud infrastructure, making high-precision ligand binding calculations available through a user-friendly interface.. How XFEP Works with High‑Precision Physics and AI‑Driven Modeling. Physics‑Driven Free Energy Perturbation Enables Accurate Binding Predictions...